BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 19771814)

  • 1. [Tenofovir, An antiviral agent with activity against HIV infections and hepatitis B].
    Taéron C
    Rev Infirm; 2009 Sep; (153):49-51. PubMed ID: 19771814
    [No Abstract]   [Full Text] [Related]  

  • 2. Tenofovir for the treatment of hepatitis B virus.
    Jenh AM; Thio CL; Pham PA
    Pharmacotherapy; 2009 Oct; 29(10):1212-27. PubMed ID: 19792994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation.
    Van Bömmel F; Schernick A; Hopf U; Berg T
    Gastroenterology; 2003 Feb; 124(2):586-7. PubMed ID: 12557178
    [No Abstract]   [Full Text] [Related]  

  • 4. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus.
    Bani-Sadr F; Palmer P; Scieux C; Molina JM
    Clin Infect Dis; 2004 Oct; 39(7):1062-4. PubMed ID: 15472862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir helps beat hepatitis B.
    TreatmentUpdate; 2003 Jan; 15(1):4. PubMed ID: 12630369
    [No Abstract]   [Full Text] [Related]  

  • 6. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
    Benhamou Y; Tubiana R; Thibault V
    N Engl J Med; 2003 Jan; 348(2):177-8. PubMed ID: 12519935
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
    Amini-Bavil-Olyaee S; Sheldon J; Lutz T; Trautwein C; Tacke F
    AIDS; 2009 Jan; 23(2):268-72. PubMed ID: 19098499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir helpful for patients with HBV.
    AIDS Patient Care STDS; 2005 May; 19(5):347. PubMed ID: 15948275
    [No Abstract]   [Full Text] [Related]  

  • 9. Tenofovir-associated kidney diseases and interactions between tenofovir and other antiretrovirals.
    Lanzafame M; Lattuada E; Rapagna F; Gottardi M; Vento S
    Clin Infect Dis; 2006 Jun; 42(11):1656-7; author reply 1658. PubMed ID: 16652329
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of drug interactions and monitoring in the prevention of tenofovir-associated kidney disease.
    Winston JA; Shepp DH
    Clin Infect Dis; 2006 Jun; 42(11):1657-8; author reply 1658. PubMed ID: 16652330
    [No Abstract]   [Full Text] [Related]  

  • 11. Tenofovir and didanosine: a dangerous liaison.
    Waters L; Maitland D; Moyle GJ
    AIDS Read; 2005 Aug; 15(8):403-6, 413. PubMed ID: 16110555
    [No Abstract]   [Full Text] [Related]  

  • 12. Tenofovir: what have over 1 million years of patient experience taught us?
    Pozniak A
    Int J Clin Pract; 2008 Aug; 62(8):1285-93. PubMed ID: 18705824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug therapy: tenofovir.
    Lok AS
    Hepatology; 2010 Aug; 52(2):743-7. PubMed ID: 20597070
    [No Abstract]   [Full Text] [Related]  

  • 14. Tenofovir disoproxil fumarate: role in hepatitis B treatment.
    Wong SN; Lok AS
    Hepatology; 2006 Aug; 44(2):309-13. PubMed ID: 16871562
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapy of chronic hepatitis B. Tenofovir--first choice in current EASL guidelines].
    MMW Fortschr Med; 2009 May; 151(22):38-9. PubMed ID: 19526965
    [No Abstract]   [Full Text] [Related]  

  • 16. Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations.
    Manfredi R
    Clin Infect Dis; 2006 May; 42(9):1345-7; author reply 1347-8. PubMed ID: 16586399
    [No Abstract]   [Full Text] [Related]  

  • 17. Tenofovir: new indication. In chronic hepatitis B: beware bone toxicity.
    Prescrire Int; 2009 Jun; 18(101):116. PubMed ID: 19637428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Congenital pyelectasis in children born from mothers on tenofovir containing therapy during pregnancy: report of two cases.
    Sabbatini F; Prati F; Borghi V; Bedini A; Esposito R; Mussini C
    Infection; 2007 Dec; 35(6):474-6. PubMed ID: 18034206
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant.
    Jiménez-Pérez M; Sáez-Gómez AB; Mongil Poce L; Lozano-Rey JM; de la Cruz-Lombardo J; Rodrigo-López JM
    Transplant Proc; 2010 Oct; 42(8):3167-8. PubMed ID: 20970638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir.
    Tan LK; Gilleece Y; Mandalia S; Murungi A; Grover D; Fisher M; Atkins M; Nelson M
    J Viral Hepat; 2009 Jul; 16(7):471-8. PubMed ID: 19457140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.